无创检测在丙肝合并终末期肾病患者中诊断晚期肝纤维化的准确性
本研究回顾性纳入139例HCV合并ESRD患者,以肝活检为金标准,评估AST/ALT比值、APRI、FIB-4、纤维化指数评分和King评分诊断晚期纤维化的准确性。FIB-4的AUROC为0.71,King评分为0.69,APRI为0.68;在ALT升高患者中准确性略有提高,但ALT正常时所有检测均不准确。
要点
- FIB-4、King评分和APRI在HCV合并ESRD患者中诊断晚期纤维化的AUROC为0.68-0.71。
- ALT升高患者中上述无创检测准确性略有提高。
- ALT正常时所有无创检测均产生不准确结果。
核心结论
- 在HCV合并ESRD患者中,FIB-4、King评分和APRI可识别晚期纤维化,AUROC范围为0.68-0.71。
- ALT升高患者检测准确性略有提高,但ALT正常患者检测结果不准确。
研究设计与样本
- 回顾性研究,纳入139例HCV合并ESRD患者,平均年龄52.8岁,76.3%男性,86.4%非裔美国人,45.3%ALT升高。
- 以肝活检组织学分析为参考标准,主要结局为晚期纤维化(桥接纤维化或肝硬化)。
主要发现
- FIB-4诊断晚期纤维化的AUROC为0.71(95%CI 0.61-0.80)。
- King评分诊断晚期纤维化的AUROC为0.69(95%CI 0.58-0.80)。
- APRI诊断晚期纤维化的AUROC为0.68(95%CI 0.59-0.79)。
- 在ALT升高患者中分析时,这些检测的准确性提高。
- 在AST和ALT正常患者中,所有检测均产生不准确结果。
关键数值与推荐
- 晚期纤维化定义为桥接纤维化或肝硬化。
- ALT正常定义为男性≤35 U/L、女性≤25 U/L。
临床怎么用
- 在HCV合并ESRD患者中可考虑使用FIB-4、King评分或APRI评估晚期纤维化,但需注意ALT正常者结果不可靠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: For patients with liver disease from hepatitis C virus (HCV) infection complicated by end-stage renal disease (ESRD), it is important to assess liver fibrosis before kidney transplantation. We evaluated the accuracy of non-invasive tests to identify advanced hepatic fibrosis in patients with HCV and ESRD. METHODS: In a retrospective study, we collected data on ratio of aspartate aminotransferase:alanine aminotransferase (AST:ALT), AST platelet ratio index (APRI), FIB-4 score, fibrosis index score, and King's score from 139 patients with ESRD and HCV infection (mean age, 52.8 y; 76.3% male; 86.4% African American; 45.3% with increased level of ALT). Results were compared with findings from histologic analyses of biopsies (reference standard). The primary outcome was detection of advanced fibrosis, defined as either bridging fibrosis or cirrhosis. Area under the receiver operating characteristic (AUROC) curves were constructed and optimal cutoff values were determined for each test. Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy were calculated. We repeated the analysis with stratification for normal levels of ALT (≤ 35 U/L for men and ≤ 25 u/L for women) and increased levels of ALT. RESULTS: FIB-4 scores identified patients with advanced fibrosis with an AUROC of 0.71 (95% CI, 0.61-0.80), the King's score with an AUROC of 0.69 (95% CI, 0.58-0.80), and the APRI with and AUROC of 0.68 (95% CI, 0.59-0.79). The accuracy of these tests increased when they were used to analyze patients with increased levels of ALT. All tests produced inaccurate results when they were used to assess patients with normal levels of AST and ALT. CONCLUSIONS: In patients with ESRD and HCV infection, FIB-4 scores, King's scores, and the APRI identify those with advanced fibrosis with AUROC values ranging from 0.68-0.71. Accuracy increased modestly when patients with increased levels of ALT were tested, but the tests produced inaccurate results for patients with a normal level of ALT.
引用
- Schmoyer CJ, Kumar D, Gupta G, et al. Diagnostic Accuracy of Noninvasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease. Clin Gastroenterol Hepatol. 2020. PMID: 32084602. doi:10.1016/j.cgh.2020.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。